Tue, Oct 21, 2014, 7:14 AM EDT - U.S. Markets open in 2 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • smartthough smartthough Feb 27, 2013 2:00 PM Flag

    One More Reason This is a Scam

     

    Check the Ownership,they give a number of 28 Institutional Holders, yet the list shows 0, NONE! Check the Insider Transactions, Purchases 175,000 shares, Sales 5.9 Million and that 14 sales and two buys to keep the suckers on the hook. As my grandfather use to tell me " You can lead a horse to water, but you can't make him drink". He also said "A Fool and His Money will soon part Company". Buy ADXS you'll be better off. GLTA

    Sentiment: Strong Sell

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Inovio Pharmaceuticals' Cancer Vaccine Demonstrates for 1st Time that a DNA-Based Therapeutic Vaccine Can Produce Immune Responses to Kill Target Cells
      -- Article in Peer-Reviewed Science-Translational Medicine Reports Strong and Durable T Cell Responses from VGX-3100, Which is Designed to Treat Cervical Dysplasias Caused by HPV Infection
      -- On-going phase II efficacy study will determine vaccine's ability to reverse disease progression to cervical cancer

      Oct 10, 2012

      BLUE BELL, Pa., Oct. 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today clinical results indicating that its VGX-3100 therapeutic synthetic vaccine is capable of not only driving robust immune responses to antigens from high risk types of human papillomavirus (HPV) infection but that these immune responses displayed a powerful killing effect on cells changed by HPV into precancerous dysplasias. This desirable effect may ultimately contribute to the regression or elimination of cervical dysplasia and cervical cancer. Inovio is currently assessing the ability of its DNA-based VGX-3100 to treat cervical dysplasias caused by HPV infection in a global phase II trial.

      Results from this phase I trial appeared today in the peer-reviewed journal, Science-Translational Medicine, in an article entitled, "Immunotherapy against HPV 16/18 generates potent Th1 and cytotoxic cellular immune responses."

      The paper reports that 100% of patients (18 of 18) enrolled in the phase I dose-escalating trial showed antigen-specific antibody responses to Inovio's vaccine, while 78% showed T-cell responses in the validated ELISpot assay. Further tests of T-cell immunity measured the ability of CD8+ T-cells from vaccinated patients to kill cells displaying HPV antigens on their surface: 91% of patients who developed T-cell responses showed the presence of CD8+ T-cells capable of this type of killing activity"

    • I see that others decided to reply, so I'll do it also:

      "January 7, 2013: PATH's malaria team partners with Inovio on new vaccine approach. Follow-on Agreement Will Lead to Clinical Trial"

      I wonder, who to believe, Bill & Melinda Gates Foundation or ..."smatthough" ?
      Any of the other who collaborate with INO like Merck and Pfizer, or "smatthough"?

    • you are surely dumb as nails...

      So you had to start another thread since you got smashed hard in the other.. Gutless punk

 
INO
12.19-0.12(-0.97%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NasdaqGSMon, Oct 20, 2014 4:00 PM EDT
Trinity Industries Inc.
NYSEMon, Oct 20, 2014 4:00 PM EDT